LMAT — LeMaitre Vascular, Inc.

Summary of LeMaitre Vascular Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Sales Growth: Q4 2025 sales increased by 16% year-over-year, with organic revenue growth at 15%.
• Gross Margin: Achieved a gross margin of 71.7%, up 240 basis points from the previous year.
• Operating Income: Increased by 47% to $18.8 million, resulting in an operating margin of 29%.
• Earnings Per Share (EPS): Q4 fully diluted EPS was $0.68, a 39% increase year-over-year.
• Cash Position: Ended 2025 with $359 million in cash and securities, with free cash flow of $74.5 million for the year.

2. Strategic Updates and Business Highlights

• Product Performance: Strong sales growth in grafts (up 27%), valvulotomes (up 20%), and shunts (up 18%). Artegraft sales grew 29% globally, with international sales reaching $1.9 million in Q4.
• Geographic Growth: EMEA region sales grew by 29%, APAC by 20%, and the Americas by 10%.
• Direct Sales Expansion: Plans to go direct in Poland and expand sales force from 160 to 170-180 reps by the end of 2026.
• Price Increases: Implemented an 8% blended price increase across the portfolio with positive customer acceptance reported.
• M&A Strategy: Actively pursuing acquisitions in open vascular and cardiac surgery markets, with 22 targets identified.

3. Forward Guidance and Outlook

• 2026 Guidance: Anticipating revenue of $280 million, representing 12% sales growth, with adjusted operating income growth of 21%. Expected EPS of $2.91, up 22% adjusted.
• Gross Margin: Projected to improve to 72.1% in 2026, driven by pricing increases and manufacturing efficiencies.

4. Bad News, Challenges, or Points of Concern

• Cyber Incident: A cyber incident in January 2026 affected certain systems, but minimal disruption to sales and operations was reported. Ongoing review and potential risks remain.
• Manufacturing Transition: Consolidation of the Chicago RFA facility into Burlington may create short-term headwinds but is expected to enhance efficiency long-term.
• Market Competition: Concerns about competitive pressures in the carotid artery stenting business and potential impacts from the CREST-2 trial results.

5. Notable Q&A Insights

• Operating Leverage: Management emphasized maintaining stable headcount while increasing sales pricing and manufacturing efficiency as key drivers for operating income growth.
• Artegraft Market Potential: The total addressable market (TAM) for Artegraft was revised upwards to $30 million, driven by strong demand and successful launches in Europe.
• APAC Market Recovery: Notable recovery in the APAC region, particularly in China, with 24% revenue growth in Q4, although Japan showed signs of softness.
• Valvulotome Performance: The 20% growth in valvulotomes attributed to a well-established sales channel and the effectiveness of the procedure, despite a flat unit market overall.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable insights from the Q&A, while also addressing challenges and potential risks faced by LeMaitre Vascular.